 Jennifer Trujillo
Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 12 | 2024 | 134 | 4.360 |
Why?
| | Hypoglycemic Agents | 21 | 2025 | 1212 | 4.010 |
Why?
| | Diabetes Mellitus, Type 2 | 22 | 2025 | 2429 | 3.520 |
Why?
| | Students, Pharmacy | 10 | 2024 | 110 | 2.790 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 9 | 2022 | 91 | 2.730 |
Why?
| | Glucagon-Like Peptides | 5 | 2020 | 49 | 1.920 |
Why?
| | Glucagon-Like Peptide 1 | 6 | 2018 | 112 | 1.610 |
Why?
| | Peptides | 7 | 2018 | 908 | 1.490 |
Why?
| | Curriculum | 9 | 2024 | 917 | 1.460 |
Why?
| | Receptors, Glucagon | 3 | 2015 | 28 | 1.380 |
Why?
| | Insulin Glargine | 4 | 2022 | 80 | 1.300 |
Why?
| | Hypoglycemia | 6 | 2022 | 425 | 1.180 |
Why?
| | Educational Measurement | 8 | 2019 | 261 | 1.160 |
Why?
| | Insulin | 8 | 2022 | 2315 | 0.990 |
Why?
| | Blood Glucose | 9 | 2020 | 2093 | 0.830 |
Why?
| | Osteoarthritis | 1 | 2025 | 181 | 0.800 |
Why?
| | Teaching | 2 | 2015 | 215 | 0.790 |
Why?
| | Liraglutide | 4 | 2016 | 29 | 0.760 |
Why?
| | Immunoglobulin Fc Fragments | 3 | 2020 | 40 | 0.750 |
Why?
| | Anti-Obesity Agents | 3 | 2016 | 53 | 0.710 |
Why?
| | Pharmacists | 3 | 2019 | 261 | 0.710 |
Why?
| | Glucagon | 1 | 2020 | 105 | 0.640 |
Why?
| | Recombinant Fusion Proteins | 3 | 2020 | 634 | 0.620 |
Why?
| | Metformin | 2 | 2020 | 312 | 0.620 |
Why?
| | Emergency Treatment | 1 | 2020 | 113 | 0.620 |
Why?
| | Weight Loss | 7 | 2025 | 725 | 0.610 |
Why?
| | Medication Therapy Management | 1 | 2019 | 74 | 0.590 |
Why?
| | Hyperglycemia | 2 | 2014 | 326 | 0.580 |
Why?
| | Patient Education as Topic | 4 | 2018 | 737 | 0.570 |
Why?
| | Societies, Pharmaceutical | 2 | 2016 | 25 | 0.570 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 197 | 0.520 |
Why?
| | Schools, Pharmacy | 3 | 2024 | 54 | 0.490 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2017 | 17 | 0.460 |
Why?
| | Humans | 40 | 2025 | 128417 | 0.460 |
Why?
| | Drugs, Investigational | 1 | 2014 | 32 | 0.460 |
Why?
| | Problem-Based Learning | 2 | 2017 | 76 | 0.460 |
Why?
| | Drug Combinations | 4 | 2018 | 323 | 0.430 |
Why?
| | Health Literacy | 1 | 2015 | 161 | 0.410 |
Why?
| | Body Weight | 4 | 2020 | 928 | 0.410 |
Why?
| | Peer Review | 1 | 2012 | 47 | 0.380 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2022 | 90 | 0.380 |
Why?
| | Drug Administration Schedule | 3 | 2020 | 751 | 0.380 |
Why?
| | Patient-Centered Care | 1 | 2016 | 501 | 0.370 |
Why?
| | Learning | 1 | 2015 | 396 | 0.350 |
Why?
| | Interpersonal Relations | 1 | 2014 | 388 | 0.350 |
Why?
| | Pancreatitis | 1 | 2010 | 128 | 0.310 |
Why?
| | Diet Records | 1 | 2009 | 80 | 0.310 |
Why?
| | Faculty, Medical | 1 | 2012 | 262 | 0.310 |
Why?
| | Cultural Competency | 1 | 2009 | 81 | 0.300 |
Why?
| | Drug Interactions | 1 | 2009 | 357 | 0.290 |
Why?
| | Cardiovascular Diseases | 2 | 2017 | 1999 | 0.290 |
Why?
| | Attitude of Health Personnel | 3 | 2015 | 1093 | 0.280 |
Why?
| | Communication | 4 | 2016 | 838 | 0.280 |
Why?
| | Peer Group | 1 | 2008 | 225 | 0.270 |
Why?
| | Empathy | 1 | 2009 | 170 | 0.270 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 999 | 0.270 |
Why?
| | Clinical Protocols | 1 | 2008 | 252 | 0.260 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 993 | 0.260 |
Why?
| | Program Evaluation | 3 | 2017 | 874 | 0.260 |
Why?
| | Obesity | 2 | 2016 | 2858 | 0.250 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1009 | 0.230 |
Why?
| | Faculty, Pharmacy | 1 | 2024 | 20 | 0.230 |
Why?
| | Spironolactone | 1 | 2004 | 28 | 0.220 |
Why?
| | Drug Utilization Review | 1 | 2004 | 56 | 0.220 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2004 | 45 | 0.220 |
Why?
| | Venoms | 2 | 2015 | 28 | 0.220 |
Why?
| | Family Practice | 1 | 2008 | 455 | 0.210 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2022 | 23 | 0.200 |
Why?
| | Injections, Subcutaneous | 2 | 2014 | 144 | 0.190 |
Why?
| | Patient Compliance | 1 | 2004 | 560 | 0.170 |
Why?
| | Administration, Intranasal | 1 | 2020 | 82 | 0.170 |
Why?
| | Professional Role | 2 | 2019 | 160 | 0.160 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 170 | 0.160 |
Why?
| | Nausea | 1 | 2020 | 107 | 0.160 |
Why?
| | Cardiovascular System | 1 | 2020 | 137 | 0.150 |
Why?
| | Internship and Residency | 1 | 2008 | 1048 | 0.150 |
Why?
| | Postprandial Period | 1 | 2018 | 103 | 0.140 |
Why?
| | Insulin, Long-Acting | 1 | 2017 | 61 | 0.140 |
Why?
| | Administration, Oral | 1 | 2020 | 754 | 0.140 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2017 | 3 | 0.140 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 1275 | 0.140 |
Why?
| | Canagliflozin | 1 | 2017 | 9 | 0.140 |
Why?
| | Treatment Outcome | 3 | 2020 | 10151 | 0.140 |
Why?
| | Perception | 1 | 2019 | 338 | 0.140 |
Why?
| | Glucosides | 1 | 2017 | 38 | 0.130 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 66 | 0.130 |
Why?
| | Professional Practice | 1 | 2016 | 64 | 0.130 |
Why?
| | Self-Management | 1 | 2018 | 162 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 5362 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1356 | 0.120 |
Why?
| | Self Care | 1 | 2018 | 368 | 0.120 |
Why?
| | Drug Approval | 1 | 2015 | 86 | 0.120 |
Why?
| | Sitagliptin Phosphate | 1 | 2015 | 31 | 0.120 |
Why?
| | Counseling | 1 | 2018 | 382 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 199 | 0.110 |
Why?
| | Pyrazines | 1 | 2015 | 86 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 587 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2015 | 137 | 0.110 |
Why?
| | Triazoles | 1 | 2015 | 147 | 0.110 |
Why?
| | Pilot Projects | 2 | 2008 | 1563 | 0.100 |
Why?
| | Adult | 6 | 2022 | 35299 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2022 | 14454 | 0.100 |
Why?
| | Comprehension | 1 | 2014 | 164 | 0.100 |
Why?
| | Community Pharmacy Services | 1 | 2012 | 45 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2616 | 0.090 |
Why?
| | Educational Status | 1 | 2014 | 470 | 0.090 |
Why?
| | Feedback | 1 | 2012 | 159 | 0.090 |
Why?
| | Pharmacy Service, Hospital | 1 | 2012 | 93 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1618 | 0.090 |
Why?
| | Male | 7 | 2022 | 62857 | 0.090 |
Why?
| | Health Care Costs | 3 | 2022 | 367 | 0.090 |
Why?
| | Heart Failure | 1 | 2004 | 2145 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1543 | 0.090 |
Why?
| | United States | 3 | 2016 | 13830 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2012 | 275 | 0.080 |
Why?
| | Female | 7 | 2022 | 68153 | 0.080 |
Why?
| | Clinical Competence | 1 | 2016 | 1013 | 0.080 |
Why?
| | Patient Safety | 1 | 2012 | 287 | 0.080 |
Why?
| | Data Collection | 1 | 2012 | 647 | 0.080 |
Why?
| | Observer Variation | 1 | 2008 | 312 | 0.070 |
Why?
| | Professional-Patient Relations | 1 | 2009 | 140 | 0.070 |
Why?
| | Boston | 1 | 2008 | 87 | 0.070 |
Why?
| | Advisory Committees | 1 | 2008 | 218 | 0.070 |
Why?
| | Acute Disease | 1 | 2010 | 964 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2008 | 316 | 0.060 |
Why?
| | Concurrent Review | 1 | 2004 | 2 | 0.060 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 112 | 0.050 |
Why?
| | Massachusetts | 1 | 2004 | 158 | 0.050 |
Why?
| | Guideline Adherence | 1 | 2008 | 521 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2004 | 128 | 0.050 |
Why?
| | Aged | 4 | 2022 | 21953 | 0.050 |
Why?
| | Animals | 1 | 2025 | 34479 | 0.050 |
Why?
| | Patient Care Team | 1 | 2008 | 605 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3020 | 0.040 |
Why?
| | Hospitalization | 1 | 2008 | 2057 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3624 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2012 | 7033 | 0.040 |
Why?
| | Middle Aged | 3 | 2012 | 30889 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1269 | 0.030 |
Why?
| | Phentermine | 1 | 2016 | 7 | 0.030 |
Why?
| | Bupropion | 1 | 2016 | 40 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2721 | 0.030 |
Why?
| | Benzazepines | 1 | 2016 | 40 | 0.030 |
Why?
| | Prospective Studies | 1 | 2008 | 7036 | 0.030 |
Why?
| | Fructose | 1 | 2016 | 106 | 0.030 |
Why?
| | Naltrexone | 1 | 2016 | 84 | 0.030 |
Why?
| | Motivation | 1 | 2019 | 546 | 0.030 |
Why?
| | Cough | 1 | 2014 | 116 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 509 | 0.030 |
Why?
| | Pharmacology, Clinical | 1 | 2012 | 9 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2014 | 661 | 0.030 |
Why?
| | Medication Reconciliation | 1 | 2012 | 30 | 0.030 |
Why?
| | Health Personnel | 1 | 2017 | 644 | 0.020 |
Why?
| | Medical Informatics | 1 | 2012 | 99 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 186 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 475 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4375 | 0.020 |
Why?
| | Quality Improvement | 1 | 2012 | 1094 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2006 | 274 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5388 | 0.010 |
Why?
|
|
Trujillo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|